Analytical Data
-
基因名
VEGF145
- Application
-
别名
VEGF145；VEGF；Vascular endothelial growth factor A. long form
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15692
-
表达区间
1-395aa
-
氨基酸序列
MTDRQTDTAPSPSYHLLPGRRRTVDAAASRGQGPEPAPGGGVEGVGARGVALKLFVQLLGCSRFGGAVVRAGEAEPSGAARSASSGREEPQPEEGEEEEEKEEERGPQWRLGARKPGSWTGEAAVCADSAPAARAPQALARASGRGGRVARRGAEESGPPHSPSRRGSASRAGPGRASETMNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
-
分子量
43.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis, the process of forming new blood vessels, which is essential for normal development and healing, as well as for pathological conditions such as cancer. Among the various isoforms of VEGF, VEGF145, a variant that is generated through alternative splicing, has gained attention due to its unique properties and potential therapeutic applications. Research has shown that VEGF145 exhibits distinct biological activities compared to other isoforms, which may influence its role in vascular permeability and endothelial cell function. Understanding the specific functions of VEGF145 could provide insights into targeted therapies for diseases characterized by abnormal angiogenesis, such as tumors or diabetic retinopathy. The recombination of VEGF145 for experimental purposes enables the study of its effects in vitro and in vivo, offering a platform to explore its mechanisms and interactions with other cellular factors. This research is critical for developing innovative therapeutic strategies aimed at modulating angiogenesis, ultimately improving outcomes in various diseases linked to abnormal blood vessel growth.
